CAS 1149705-71-4: XL-888

XL888

XL888 is an orally bioavailable Hsp90 inhibitor, blocking cell proliferation and inducing tumor regression with an IC50 of 24 nM.

5-(((R)-Sec-Butyl)Amino)-N1-((3-Endo)-8-(5-(Cyclopropanecarbonyl)Pyridin-2-Yl)-8-Azabicyclo[3.2.1]Octan-3-Yl)-2-Methylterephthalamide

XL888 is a selective and potent inhibitor of heat shock protein 90 (HSP90), which is a molecular chaperone involved in the proper folding, stability, and function of many client proteins, including those critical in cancer progression. Sourced from rigorous medicinal chemistry processes, XL888 is designed to bind to the ATP-binding site of HSP90, thereby inhibiting its chaperone activity. This inhibition leads to the degradation of client proteins that are essential for tumor growth and survival. The mode of action of XL888 involves the destabilization of several oncogenic proteins that rely on HSP90 for maintenance. As a result, it disrupts multiple signaling pathways simultaneously, which is beneficial in preventing cancer cells from adapting and developing resistance. Given its mechanism, XL888 holds significant potential in cancer research, particularly in studying its synergistic effects with other therapeutic agents in preclinical models. Research applications include exploring its efficacy in various types of malignancies, examining the biochemical pathways involved, and studying its pharmacodynamics and pharmacokinetics for future clinical trials.